Improving the world

CEO of FutuRx Ltd., the Israeli Biotechnology accelerator. FutuRx is dedicated to transforming breakthrough discoveries into novel medicines by applying a unique structure: experienced biotech management combined with an equally-balanced partnership among its three founding organizations. FutuRx’s role is as a catalyst for drug development. Through its dedicated and unique organizational structure, the company is bridging the gap between concept and clinical proof-of-concept.

 

FutuRx

After winning a tender of the Office of the Chief Scientist (OCS) in Israel, FutuRx was established in January 2014 by OrbiMed Israel Partners, Johnson & Johnson Innovation – JJDC, and Takeda Pharmaceutical Company, through its venture group Takeda Ventures Inc. FutuRx intends to grow 30-40 biotech startup companies during the course of the 8-year tender.

 

Home

FutuRx is located in the Weizmann Science Park in Ness Ziona (near the Weizmann Institute of Science), Israel. Its 1200 square-meter facility consits of fully-equipped 330 square-meter laboratories and offices, with space for more than 10 project companies in parallel.

 

Biography

Dr. Zisman’s expertise is in building value via licensing, partnering, financing and marketing of early stage technologies.

 

Prior to Joining FutuRx, Dr. Zisman served as the CEO of Hadasit Medical Research Services & Development Ltd., the Technology Transfer Organization (TTO) and commercial arm of Hadassah Medical Organization in Jerusalem, Israel.

 

Before joining Hadasit, Dr. Zisman served as the Chief Business Officer of Yeda, the technology transfer arm of the Weizmann Institute of Science.

 

Dr. Zisman holds an MBA from the Marshall Business School, University of Southern California, a Ph.D. from the Weizmann Institute of Science, and a B.Pharm. degree from the Hebrew University of Jerusalem.